Syntheses and activities of backbone-side chain cyclic octapeptide ligands with N-functionalized phosphotyrosine for the N-terminal SH2-domain of the protein tyrosine phosphatase SHP-1

Journal of Peptide Science

Volumn 16, Issue 8, 2010, Pages 403-413

  Zoda, Mohammad Safa ^a   Zacharias, Martin ^b   Reissmann, Siegmund ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Backbone cyclization; Dipeptide building blocks; Ligand modelling; N functionalized Tyr; O acylation; Phosphorylation; SH2 ligands; Stimulation of SHP 1

Indexed keywords

LACTAM; OCTAPEPTIDE; PHENOL; PHOSPHOTYROSINE; PROTEIN SH2; PROTEIN TYROSINE PHOSPHATASE SHP 1; CYCLOPEPTIDE; OLIGOPEPTIDE;

ALKYLATION; AMINO TERMINAL SEQUENCE; ARTICLE; ENZYME ACTIVITY; HYDROPHOBICITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; CHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; SRC HOMOLOGY DOMAIN; SYNTHESIS; THIN LAYER CHROMATOGRAPHY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PHOSPHOTYROSINE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SRC HOMOLOGY DOMAINS;

EID: 77957309353     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1256     Document Type: Article

References (48)

1. Zoda MS, Reissmann S. Backbone cyclization of peptides via N-functionalized phosphorylated tyrosine. In Peptides 2008, Lankinen H, Naervaenen A (eds). FIPS: Helsinki, 2009; 138-139.
2. Zhang J, Somani AK, Siminovitch KA. Roles of SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Immunology 2000; 12: 361-378.
3. Keilhack H, Müller M, Böhmer S-A, Frank C, Weidner KM, Birchmeier W, Ligensa T, Berndt A, Kosmehl H, Günther B, Müller T, Birchmeier C, Böhmer FD. Negative regulation of Ros receptor tyrosine kinase signaling. An epithelial function of the SH2 domain protein tyrosine phosphatase SHP-1. J. Cell Biol. 2001; 152: 325-334.
4. Li L, Dixon JE. Form, function, and regulation of protein tyrosine phosphatases and their involvement in human diseases. Semin. Immunol. 2000; 12: 75-84.
5. Seo D-W, Li H, Qu CK, Oh J, Kim JS, Diaz T, Wei B, Han JW, Stetler- Stevenson WG. Shp-1mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J. Biol. Chem. 2006; 281: 3711-3721.
6. Wu C, Guan Q, Wang Y, Zhao ZJ, Zhou GW. SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. J. Cell Biochem. 2003; 90: 1026-1037. (Pubitemid 37467118)
7. Kamata T, Yamashita M, Kimura M, Murata K, Inami M, Shimizu C, Sugaya K, Wang CR, Taniguchi M, Nakayama T. Src-homology 2 domain - containing tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation. J. Clin. Invest. 2003; 111: 109-119.
8. Gavrieli M, Murphy KM. Association of Grb-2 and PI3K p85 with phosphotyrosyl peptides derived from BTLA. Biochem. Biophys. Res. Com. 2006; 345: 1440-1445.
9. Chemnitz JM, Lanfranco AR, Braunstein I, Riley JL. B and T lymphocytes attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs. J. Immunol. 2006; 176: 6603-6614.
10. Pathak MK, Yi T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol. 2001; 167: 3391-3397. (Pubitemid 32852583)
11. Yang J, Liang X, Niu T, Meng W, Zhao Z, Zhou GW. Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1. J. Biol. Chem. 1998; 273: 28199-281207.
12. Yang J, Chen Z, Niu T, Liang X, Zhao ZJ, Zhou GW. Structural basis for substrate specificity of protein-tyrosine phosphatase SHP-1. J. Biol. Chem. 2000; 275: 4066-4071.
13. Frank C, Burkhardt C, Imhof D, Ringel J, Zschörnig O, Wieligmann K, Zacharias M, Böhmer F. Effective dephosphorylation of src substrates by SHP-1. J. Biol. Chem. 2004; 279: 11375-11383.
14. Massa PT, Saha S, Wu C, Jarosinski KW. Expression and function of the protein tyrosine phosphatase SHP-1 in oligodendrocytes. Glia 2000; 29: 376-385. (Pubitemid 30121427)
15. Abu-Dayyeh I, Shio MT, Sato S, Akira S, Cousineau R, Oliver M. Leishmania-induced IRAK-1 inactivation is mediated by SHP-1 interacting with an evolutionarily conserved KTIM motif. PLoS Negl. Trop. Dis. 2008; 2: e305 (www.plosntd.org).
16. Nadan D, Reiner NE. Leishmania donovani engages in regulatory interference by targeting macrophage protein tyrosine phosphatase SHP-1. Clin. Immunol. 2005; 114: 266-277.
17. Imhof D, Wavreille AS, May A, Zacharias M, Tridandapani S, Pei D. Sequence specificity of SHP-1 and SHP-2 Src homology 2 domains. Critical roles of residues beyond the pY+3 Position. J. Biol. Chem. 2006; 281: 20271-20282.
18. Sweeney MC, Wavreille A-S, Park J, Butchar JP, Tridandapani S, Pei D. Decoding protein - protein interactions through combinatorial chemistry: sequence specificity of SHP-1, SHP-2, and SHIP SH2 domains. Biochemistry 2005; 44: 14932-14947.
19. Daeron M, Jaeger SD, Pasquier L, Vivier E. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol. Rev. 2008; 224: 11-43.
20. Beebe KD, Wang P, Arabaci G, Pei D. Determination of the binding specifity of the SH2 domains of protein tyrosine phosphatase SHP-1 through the screening of a combinatorial phosphotyrosyl peptide library. Biochemistry 2000; 39: 13251-13260.
21. Imhof D, Wieligmann K, Hampel K, Nothmann D, Zoda MS, Schmidt- Arras D, Böhmer F, Reissmann S. Design and biological evaluation of linear and cyclic phosphopeptide ligands of the N-terminal SH2 domain of protein tyrosine phosphatase SHP-1. J. Med. Chem. 2005; 48: 1528-1539.
22. Wieligmann K, Castro LF, Zacharias M. Molecular dynamics simulations on the free and complexed N-terminal SH2 domain of SHP-2. In Silico Biol. 2002; 2: 305-311. (Pubitemid 35469205)
23. Mueller B, Besser D, Kleinwaechter P, Arad O, Reissmann S. Synthesis of N-carboxyalkyl and N-aminoalkyl functionalized dipeptide building units for the assembly of backbone cyclic peptides. J. Pept. Res. 1999; 54: 383-393.
24. Besser D, Mueller B, Agricola I, Reissmann S. Synthesis of differentially protected N-acylated reduced pseudodipeptides as building units for backbone cyclic peptides. J. Pept. Sci. 2000; 6: 130-138.
25. Schumann C, Seyfarth L, Greiner G, Reissmann S. Synthesis of different types of dipeptide building units containing N- or C-terminal arginine for the assembly of backbone cyclic peptides. J. Pept. Res. 2000; 55: 428-435.
26. Schumann C, Seyfarth L, Greiner G, Paegelow I, Reissmann S. Synthesis and biological activities of new side chain and backbone cyclic bradykinin analogues. J. Pept. Res. 2002; 60: 128-140.
27. Reissmann S, Imhof D. Development of conformationally restricted analogues of bradykinin and somatostatin using constrained amino acids and different types of cyclization. Curr. Med. Chem. 2004; 11: 2823-2844.
28. Besser D, Müller B, Kleiwächter P, Greiner G, Seyfarth L, Steinmetzer T, Arad O, Reissmann S. Synthesis and characterization of octapeptide somatostatin analogues with backbone cyclization: comparison of different strategies, biological activities and enzymatic stabilities. J. Prakt. Chem. 2000; 342: 537-545.
29. Clark TD, Sastry M, Brown C, Wagner G. Solid-phase synthesis of backbone-cyclized β-helical peptides. Tetrahedron 2006; 62: 9533-9540. (Pubitemid 44301325)
30. Hariton-Gazal E, Rosenbluh J, Zakai N, Fridkin G, Brack-Werner R, Wolff H, Devaux C, Gilon C, Loyter A. Functional analysis of backbone cyclic peptides bearing the arm domain of the HIV Rev protein: characterization of the karyophilic properties and inhibition of Rev-induced gene expression. Biochemistry 2005; 44: 11555-11566.
31. Qvit N, Hatzubai A, Shalev DE, Friedler A, Ben-Neriah Y, Gilon C. Design and synthesis of backbone cyclic phosphorylated peptides: the IκB model. Biopolymers (Peptide Science) 2008; 91: 157-168.
32. Hess S, Linde Y, Ovadia O, Safrai E, Shalev DE, Swed A, Halbfinger E, Lapidot T, Winkler I, Gabinet Y, Feier A, Yarden D, Xiang Z, Portillo FP, Haskell-Luevano C, Gilon C, Hoffmann A. Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. J.Med. Chem. 2008; 51: 1026-1034.
33. Bitan G, Muller D, Kasher R, Gluhov EV, Gilon C. Building units for N-backbone cyclic peptides. Part 4. Synthesis of protected Nα- functionalized alkyl amino acids by reductive alkylation of natural amino acids. J. Chem. Soc., Perkin Transactions 1: Organic and Bioorganic Chem. 1997; 10: 1501-1510.
34. Gazal S, Gellerman G, Gilon C. Novel Gly building units for backbone cyclization: synthesis and incorporation into model peptides. Peptides 2003; 24: 1847-1852. (Pubitemid 38177620)
35. Loffet A, Zhang HX. Allyl based groups for side chain protection of amino acids. Int. J. Pept. Prot. Res. 1993; 42: 346-351.
36. Guibe F. Allylic protecting groups and their use in a complex environment part ii: allylic protecting groups and their removal through catalytic palladium π-allylmethodology. Tetrahedron 1998; 54: 2967-3042. (Pubitemid 28153288)
37. Nahm S, Weinreb S. N-Methoxy-N-methylamides as effective acylating agents. Tetrahedron Lett. 1981; 22: 3815-3818.
38. Fehrentz J-A, Castro B. An efficient synthesis of optically active α-(t-butoxycarbonyl-amino)-aldehydes from α-amino acids. Synthesis 1983; 676-678.
39. 2-domain of protein tyrosine phosphatase SHP-1. J. Pept. Sci. 2005; 11: 390-400.
40. Gothe R, Seyfahrth L, Schumann C, Agricola I, Reissmann S, Lifferth A, Birr C, Filatova MP, Kritsky A, Kibirev V. Combination of allyl protection and Hycram™-linker technology for the synthesis of peptides with problematical amino acids and sequences. J. Prakt. Chem. 1999; 341: 369-377.
41. Perich JW. Synthesis of Tyr(P)-containing peptides via "on-line" phosphorylation of the tyrosine residue on the solid phase. Lett. Pept. Sci. 1996; 3: 127-132.
42. Perich JW. Synthesis of phosphopeptides via global phosphorylation onthe solid phase: resolution of H-phosphonate formation. Lett. Pept. Sci. 1998; 5: 49-55.
43. Attard TJ, O'Brien-Simpson N, Reynolds EC. Synthesis of phosphopeptides in the Fmoc mode. Int. J. Pept. Res. Ther. 2007; 13: 447-468.
44. Yu HM, Chen ST, Wang KT. Enhanced coupling efficiency in solid-phase peptide synthesis by microwave irradiation. J. Org. Chem. 1992; 57: 4781-4784.
45. Brandt M, Gammeltoft S, Jensen KJ. Microwave heating for solid-phase peptide synthesis: general evaluation and application to 15-mer phosphopeptides. Inter. J. Pept. Res. and Ther. 2006; 12: 349-357.
46. Paul R. O-Acylation of tyrosine during peptide synthesis. J. Org. Chem. 1963; 28: 236-237.
47. Girin SK, Svachkin Yu P. Natural peptides and their analogs. XV. Study of the effect of a solvent on the rates of O- and N-acylation under peptide synthesis conditions using the method of p-nitrophenylesters. Zh. Obshch. Khim. 1978; 48: 1887-1891.
48. Martinez J, Tolle JC, Bodanszky M. Side reactions in peptide synthesis: X. Prevention of O-acylation during coupling with active esters. Int. J. Pept. Prot. Res. 1969; 13: 22-27.